2020
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion 2020, 60: 1867-1872. PMID: 32654201, PMCID: PMC7606221, DOI: 10.1111/trf.15798.Peer-Reviewed Original ResearchConceptsReduced intensity conditioning regimenIntensity conditioning regimenExtracorporeal photopheresisConditioning regimenChronic extensive GVHDTotal body irradiationChronic graftECOG-ACRINExtensive GVHDGVHD prophylaxisHost diseaseMycophenolate mofetilCell infusionMulticenter trialTolerogenic stateAggressive lymphomaBody irradiationMedian timeMyelodysplastic syndromeGrade 3Day 100PatientsCellular therapyConsecutive daysAdequate engraftment
2016
Autologous Stem Cell Mobilization in the Age of Plerixafor
Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clinical Lymphoma Myeloma & Leukemia 2016, 16: 411-416. PMID: 27245311, DOI: 10.1016/j.clml.2016.04.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CD34BenzylaminesCyclamsFemaleGraft SurvivalGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHematopoietic Stem CellsHeterocyclic CompoundsHumansLymphomaMaleMiddle AgedMultiple MyelomaTreatment OutcomeWorkflowConceptsStem cell mobilizationCell mobilizationPlerixafor useG-CSFAutologous stem cell transplantationAutologous stem cell mobilizationGranulocyte-colony stimulating factor (G-CSF) mobilizationDose of plerixaforLess platelet transfusionsStem cell transplantationCD34 cells/Treatment of myelomaCells/High-risk factorsEnough stem cellsStem cellsHematologic tolerancePosttransplantation therapyRelapsed lymphomaPlatelet transfusionsCell transplantationRisk factorsFactor mobilizationPatientsPlerixafor
2011
Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution
Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution. Clinical Lymphoma Myeloma & Leukemia 2011, 11: 267-272. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.Peer-Reviewed Original ResearchConceptsStem cell mobilizationEnough stem cellsMultiple myelomaCell mobilizationG-CSFPrevious mobilizationGranulocyte colony-stimulating factorNon-Hodgkin lymphomaStem cellsG-CSF mobilizationColony-stimulating factorPrevious chemotherapyPrevious therapyMobilization failurePoor mobilizationEvening injectionsCD34 countHigh riskPatientsPlerixaforCell countCost-effective useMyelomaLenalidomideChemotherapy
2002
Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene
Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leukemia Research 2002, 26: 1077-1083. PMID: 12443879, DOI: 10.1016/s0145-2126(02)00059-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArginineButyratesCell SurvivalCyclic AMPDiphtheria ToxinDose-Response Relationship, DrugDrug SynergismHumansInterleukin-2Interleukin-2 Receptor beta SubunitLeukemiaLymphomaReceptors, InterleukinReceptors, Interleukin-2Recombinant Fusion ProteinsResponse ElementsSecond Messenger SystemsUp-RegulationConceptsCutaneous T-cell lymphomaIL-2R expressionNon-Hodgkin lymphomaArginine butyrateIL-2RLow affinity IL-2RHistone deacetylaseDirect growth-inhibitory effectB-cell non-Hodgkin lymphomaHigh-affinity IL-2 receptorLeukemia cellsCAMP response elementT-cell lymphomaIL-2 receptorNative diphtheria toxinGrowth inhibitory effectsClinical trialsP75 subunitAchievable concentrationsResponse rateVitro dataDAB389IL-2Interleukin-2 geneTumor cellsLymphoma cellsLymphoma of the Skin
Connors JM, Hsi ED, Foss FM. Lymphoma of the Skin. Hematology 2002, 2002: 263-282. PMID: 12446427, DOI: 10.1182/asheducation-2002.1.263.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsHumansLymphomaLymphoma, B-CellLymphoma, T-Cell, CutaneousSkin NeoplasmsConceptsT-cell lymphomaCutaneous lymphomasNew World Health Organization classification systemCutaneous anaplastic large cell lymphomaWorld Health Organization classification systemPeripheral T-cell lymphomaCutaneous T-cell lymphomaAnaplastic large cell lymphomaCurrent optimal treatmentLarge cell lymphomaB-cell lymphomaMycosis fungoidesSkin lymphomaHodgkin's lymphomaOptimal treatmentStandard treatmentCell lymphomaEffective modalityLymphoma entitiesTreatment approachesLymphomaLymphoma classificationDiseaseSkinTreatment